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A Ab bs st tr ra ac ct t    Osteoporosis is characterized by decreased bone mineral density and 
mechanistic imbalances of bone tissue that may result in reduced skeletal 
strength and an enhanced susceptibility to fractures. Osteoporosis in its most 
common form affects the elderly (both sexes) and all racial groups of human 
beings. Multiple environmental risk factors like acquired immune deficiency 
syndrome (AIDS) are believed to be one of the causes of osteoporosis. 
Recently a high incidence of osteoporosis has been observed in human 
immunodeficiency virus (HIV) infected individuals. The etiology of this 
occurrence in HIV infections is controversial. This problem seems to be more 
frequent in patients receiving potent antiretroviral therapy. In AIDS, the 
main suggested risk factors for the development of osteoporosis are use of 
protease inhibitors, longer duration of HIV infection, lower body weight 
before antiretroviral therapy, high viral load. Variations in  serum 
parameters like osteocalcin, c-telopeptide, levels of elements like  Calcium, 
Magnesium, Phosphorus, concentration of vitamin-D metabolites, lactate 
levels, bicarbonate concentrations, amount of alkaline phosphatase are 
demonstrated in the course of development of osteoporosis. 
OPG/RANKL/RANK system is final mediator of bone remodeling. Bone 
mineral density (BMD) test is of added value to assess the risk of 
osteoporosis in patients infected with AIDS. The biochemical markers also 
aid in this assessment. Clinical management mostly follows the lines of 
treatment of osteoporosis and osteopenia.  
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1.  INTRODUCTION 
Osteoporosis is a significant cause of morbidity and mortality worldwide with an estimated ten 
million people in the United States already living with this disease [1]. It is a disease characterized by 
abnormalities in the amount and architectural arrangement of bone tissue, which lead to impaired 
skeletal strength and an increased susceptibility to fractures [2]. Bone is composed of organic 
component consisting of collagen which gives bone its flexibility, and a mineral component that 
includes calcium and phosphate salts, which combine to form hydroxyapatite crystals and add hardness 
to the collagen matrix. Osteoporotic condition manifests reduced bone mass with a loss of both 
collagen and minerals.  Inspite of this loss, the collagen - calcium ratio is maintained at normal levels. 
However the reduced levels of both collagen and calcium compromise the bone strength leading to risk 
of fracture. Osteoporosis is characterized as either primary or secondary. Primary osteoporosis occurs 
in both sexes at all ages but often follows menopause in women and occurs later in life in men. In 
contrast secondary osteoporosis is a result of medication, other conditions, or diseases [3]. Many of the 
commonly occurring diseases like endocrine disorders, malabsorption disorders, bone marrow 
disorders and inflammatory diseases were reported to be associated with osteoporosis. In addition 
AIDS or HIV infection is also reported to play an important role in osteoporosis.  In the recent days, 
high incidence of osteoporosis has been observed in HIV infected individuals [4-8]. 
AIDS is one of the known multiple environmental risk factors of osteoporosis [9]. HIV infection is 
associated with numerous metabolic and endocrine complications, leading to loss of appetite and 
hypogonadism. Medication during therapy also affect bone metabolism and contribute to bone loss 
[4,5]. Bone remodeling process is altered in HIV-infections which contributes to bone loss [6].  Weight 
loss, reduced lean body mass, and impaired functional capacity are the factors which may further 
predispose HIV infected individuals with wasting to bone loss.  Reduced bone mineral density (BMD) 
has been demonstrated in HIV-infected men with hypogonadism [7] as well as in non-wasted HIV 
infected men [8]. Anabolic effects of testosterone and progressive resistance training therapy on lean 
body mass and muscle function in men with AIDS wasting have recently been reported [10,11]. 
Osteoporosis problem seems to be more frequent in patients receiving potent antiretroviral therapy, 
although a specific contribution of the drugs used in different combination regimens is yet to be 
established [12-15]. 
  The introduction of highly active antiretroviral therapy (HAART) with  the use of protease 
inhibitors (PI) has resulted in significant reductions in morbidity and mortality from HIV infection in 
recent years [16,17]. Practitioners have now become more cautious in early initiation of HAART in 
light of reports concerning serious and potentially irreversible toxicities associated with numerous 
antiretroviral drugs [18-24]. These toxicities include the development of diabetes mellitus, insulin 
resistance, hyperlipidemia, lipodystrophy and lactic acidosis [19-24]. The current review focuses on  
the possible factors that affect bone turnover and cause related bone disorders in AIDS.  
2.  EPIDEMIOLOGY OF OSTEOPOROSIS 
A. MAGNITUDE OF THE PROBLEM 
The number of people considered to have osteoporosis depends entirely on the way the condition  
is   defined  in   practice.   A committee  of  the  World  Health  Organization  (WHO) recommended 
the definitions shown in Table-1 [25]. It is possible to diagnose and treat osteoporosis (bone density 
levels more than 2.5 standard deviations (SD) below the young normal mean) prior to the occurrence of 
fractures (established osteoporosis). This avoids the need to restrict treatment to end-stage disease, 
where it may be of limited effectiveness. It also circumvents the conceptual confusion that previously 
existed when a fracture occurred, without any change in underlying bone density [26].      Women with  
bone  density levels between 1.0 and  2.5 SD below young normal mean levels have low bone mass, or 
osteopenia. Thus perimenopasual women with bone density that is 1 SD below the young normal mean 
might not have pathologically low bone mass but still they are at sufficiently high risk of fracture over 
their remaining lifetime that preventive therapy is indicted [27]. This is particularly important since 
currently available treatments can conserve existing bone mass but cannot restore osteoporotic bone to 
biomechanical normality [28]. Int. J. Med. Sci. 2004 1(3): 152-164  154 
Table 1:  World Health Organization Definition of Osteoporosis 
   
Bone  Disorder  Bone Density in standard deviation 
(below the young adult mean) 
Normal >1 
Osteopenia 1-2.5 
Osteoporosis >2.5 
Severe Osteoporosis  >2.5 with fracture 
             Source of table – Reference [25] 
B. RISK FACTORS FOR OSTEOPOROSIS IN AIDS 
The risk factors for osteoporosis are fairly straight forward (fig 1). 
Fig.1 Schema of the object of environmental and genetic risk factors on the interaction between bone 
strength and trauma that leads to osteoporotic fracture. Source of Fig. - Reference [29] 
 
 
Osteoporosis in its most common form occurs in  both the sexes of elderly and all racial groups 
affecting the BMD. The variations in bone mineral density in men and women are shown in fig. 2 [29].     
A person’s bone mass later in life is determined by the maximal bone mass achieved in young   
adulthood,   as well  as  by the subsequent rate of bone loss.  At the of age 70 years, these two 
determinants of bone mass are equally important [30]. The bone loss results from age-related factors 
that occur universally in the population and account for slow bone loss over life in both sexes. An 
accelerated phase of bone loss is associated with the menopause in women and hypogonadism in some 
men; and from medical and surgical conditions that produce secondary osteoporosis [28]. Thus race 
and sex differences in osteoporosis are explained in part by the heritability of skeletal size. Bone mass 
is greatest in those of African heritage, who have the lowest fracture rates, and is least in Caucasian 
women of Northern European origin, who have the highest fracture rates [32]. Similarly the accelerated 
phase of bone loss in perimenopasual women is superimposed upon the slower, age-related bone loss 
seen in both sexes and explains in part the two fold higher incidence of fractures among women than 
men later in life [28]. Other genetic risk factors play a major role in the heritability of many 
components of bone strength. There are a small number of cytogenetic [32,33] and monogenetic 
diseases causing osteoporosis [34-39]. Quantitative traits in bone strength in the normal population do 
not conform to a monogenetic mode of inheritance. The common form of osteoporosis is generally 
considered to be polygenic arising from the interactions of common polymorphic alleles at quantitative 
trait loci (QTL) with multiple environmental factors. Finding the genes underlying osteoporosis 
typically requires identification of its key heritable phenotypes and demonstrating in family and 
population studies that these phenotypes are coinherited with specific alleles. With progress in 
developing statistical methods to detect QTL and biochemical techniques to identify and map abundant 
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polymorphisms throughout the genome studies [40,41] for identifying the susceptibile genes for 
osteoporosis made easy for timely study. 
Microbial genome sequencing is likely to play an increasingly important role in the analysis of 
newly discovered human genes and provide further clues to the molecular basis of the diseases [42]. 
Because of the close correspondence among mammalian genomes, it is a hope that identification of the 
genes underlying bone strength in mammals such as the mouse [43] will be of major assistance for 
human studies. The identification of susceptibile genes for osteoporosis is expected to be a major 
contributing factor toward the long-term goal of understanding the molecular biology of the normal 
variation in bone strength and how it may be modified to prevent osteoporotic fractures. As with all 
genetic studies in humans, these scientific advances are need to be made in an environment of legal and 
ethical safeguards that are acceptable to the general public [44]. 
Fig 2. Normal variation (mean and 2 8D) and change in BMD with age in healthy men (black circle) 
and women in (open circle) (Normal population Data base, DPX-IQ Reference Manual, Documentation 
Version 5/96, Lunar Corp., Maidson, WI). Peak bone mass at hip and spine for measurement on Lunar 
machines is taken as the mean BMD between age 20 and 40 yr, but this age range varies with DXA 
machine manufacture. Source of Fig. - Reference [29] 
 
 
In AIDS, the mainly suggested risk factors for the development of osteopoenia and osteoporosis 
are the use of  protease inhibitors,  longer  duration of  HIV infection,  high viral load, high lactate 
levels, low bicarbonate levels, raised alkaline phosphatase level, and lower body weight before 
antiretroviral therapy. There have also been a few case reports of pathologic fractures in AIDS patients 
with antiretroviral therapy-induced osteopenia and osteoporosis. The underlying mechanism triggering 
bone loss in HIV infected patients is still unknown [3]. 
3.  BONE TURNOVER 
A. BONE REMODELING 
Growth in bone size and strength occurs during childhood, but bone accumulation is not 
completed until the cessation of linear growth (till the third decade of life). Even after bone 
accumulation has ended, there is a constant state of remodeling with repeated cycles of resorption 
followed by the deposition of new bone [3]. 
The cellular process of bone activity by which both cortical and cancellous bone is maintained is 
referred to as bone remodeling. This bone remodeling process takes place in discrete packets known as 
multicellular units [45]. Initially, a cell from the hematopoietic granulocyte-macrophage colony-
forming unit lineage (along a bone surface) is activated and proliferates or transforms into an osteoclast 
[46].  An osteoclast creates bone cavity and subsequently, osteoblasts, derived from pleuripotent 
mesenchymal stem cells of the bone marrow, fill in the area of resorption with type 1 collagen [47]. 
Type I collagen ultimately becomes mineralized, probably as a function of the osteoblasts, thereby 
completing the process of new bone formation. There is an interdependency of the osteoclastic and 
osteoblastic activities where by osteoclasts are initially recruited to a particular site on the bone 
surface, and when their task is completed, they signal the osteoblasts to attend to that same site. This Int. J. Med. Sci. 2004 1(3): 152-164  156 
interrelationship is known as coupling and is crucial link in the chain of bone-remodelling events [48]. 
A situation that interferes with coupling process or that causes imbalances between bone forming and 
resorbing relationship leads to significant loss of bone over the time. 
Regulation of the bone-remodeling process is complex. Undoubtedly, there are numerous systemic 
hormones, such as parathyroid hormone, 1, 2 5-dihydroxy-vitamin D (calcitriol), calcitonin, estrogens, 
and androgens  that regulate the process. Vitamin D is recognized as a stimulator of osteoclastic 
formation and a promoter of osteoblast differentiation [49]. There are also numerous local factors that 
play an important role in the physiology of bone remodeling like interleukins (IL-1 and IL-6), 
transforming growth factors (TGF), prostaglandins, tumor necrosis factor (TNF), lymphotoxin, colony 
stimulating factors (CSF), and gamma interferons [50-53]. 
OPG/RANKL/RANK system is  the dominant, final mediator of osteoclastogenesis. This system 
explains the precise mechanisms by which preosteoblastic stromal cells control the  osteoclast 
development.  It is a specific factor produced by preosteoblastic/stromal cells that is both necessary and 
sufficient for osteoclast development. Osteoprotegerin (OPG) is a secreted soluble member of the 
tumor necrosis factor receptor superfamily (TNFR), also known as osteoclastogenesis inhibitory factor 
(OCIF) [54,55].  It has specificity for OPG/OCIF function for inhibiting osteoclast differentiation.  The 
initial cloning and characterization of OPG as a soluble, decoy receptor belonging to the TNF receptor 
superfamily is the first step that eventually led to an unraveling of this system. Soon thereafter, the 
molecule blocked by OPG, initially called OPG-ligand/osteoclast differentiating factor (ODF).     
RANKL, is the key mediator of osteoclastogenesis in both a membrane-bound form expressed on 
preosteoblastic/stromal cells as well as a soluble form. RANKL, in turn, binds to its receptor, RANK, 
on osteoclast lineage cells. The decisive role played by these factors in regulating bone metabolism was 
demonstrated by the findings of extremes of skeletal phenotypes (osteoporosis vs. osteopetrosis) in 
mice with altered expression of these molecules. Identifying the factors regulating this system, the 
signaling mechanisms involved in the RANKL/ RANK pathway, and finally, potential alterations in 
this system in metabolic bone disorders that develop during HIV infections are crucial in understanding 
the mechanism underlying osteoclastogenesis in this particular type [56]. 
B. INTERACTIONS BETWEEN SKELETAL , IMMUNE AND HORMONAL SYSTEMS 
The entry of HIV-1 into target cells requires the binding of the viral envelope glycoprotein (Env) 
with the target cell CD4 and an additional target cell co-receptor [57].
 The co-receptors required for the 
fusion of the T cell-tropic and macrophage-tropic viruses with their target cells have now been 
identified to be fusin and CCR-5, respectively [58,59].  Fusin is a 7 TM domain protein with significant 
amino acid sequence homology to the IL-8 receptors. A CXC chemokine, PBSF/SDF-1, has recently 
been identified to be a ligand for fusin [60,61] The identification of CCR-5 as the co-receptor for 
macrophage-tropic viruses is consistent with an earlier report identifying the CCR-5 ligands (RANTES, 
MIP-1α and MIP-1β) as the major HIV suppressive factors produced by CD8
+ T cells for macrophage-
tropic, but not T cell tropic, HIV isolates [62]. Besides fusin and CCR-5, use of other chemokine 
receptors such as CCR-2B and CCR-3 by a minority of HIV isolates has also been reported [63]. 
The hypothesis that the systemic activation of T cells in vivo leads to an osteoprotegerin ligand-
mediated increase in osteoclastogenesis and bone loss [64]. This explains the interaction of HIV 
infection and bone mineralization. When the homeostasis between RANK/RANKL- osteoprotegerin is 
lost, there is an increased incidence of loss of bone mineral density. Interactions between cells of 
skeletal and immune system are important for the maintenance of bone homeostasis [65]. These 
cellular circuits are in part mediated by specific cytokines and changes in levels of these mediations 
may result in altered bone remodeling and disease [65-67]. Cytokines such as IL-1, IL-6, IL-11 and 
TNF-α may stimulate osteoclast activity [66-68] and enhanced IL-6 levels appear to play a pathogenic 
role in the enhanced bone resorption of post menopasual osteoporosis [69]. Some of these cytokines 
may also inhibit bone formation exerted by their negative regulatory effects on osteoblasts [65, 70,71]. 
This inhibitory effect on osteoblats combined with stimulation of osteoclasts suggest a pathogenic role 
for these cytokines in bone disorders characterized by increased resorption combined with decreased 
formation of bone [65].  
Persistent activation of proinflamatory cytokines such as IL-1 and in particular TNF- α  appears to 
play an important pathogenic role in HIV [72-75]. This proinflamatory activation may enhance HIV Int. J. Med. Sci. 2004 1(3): 152-164  157 
replication, contributing to the development of immunodeficiency and certain clinical manifestations 
[74,75] and also be related to the endocrine abnormalities seen in HIV infected individuals [76,77]. 
Vitamin D metabolites and elements like Calcium, Magnesium, Phosphorus have complex effects in 
the bone system, with stimulatory effects on both formation and resorption [65,78]. 
Estrogen deficiency causes an increase in osteoclastic resorbing capacity [79-81]. Estrogen 
deficiency both directly and indirectly decreases the efficiency of intestinal and renal calcium 
absorption and reabsorption respectively. Testosterone deficiency in men is the major identifiable 
cause of male osteoporosis. It has analogous mineral metabolism effects. Evidence in support of 
gonadal hormone deficiency as the cause of increasing bone resorption is that specific receptors for 
estrogen and testosterone have been identified on the surface of the bone cells [82]. 
4.  BONE MINERAL DENSITY IN HIV INFECTIONS 
Bone mineral density is widely accepted as a measure of bone strength. BMD measurements have 
been shown to correlate strongly with the load bearing capacity of the hip and spine and with the risk 
of fracture. In patients with osteoporosis, there is a four fold to five fold increase in risk for fracture. 
And for patients with osteoporosis and a history of fracture, the risk of another fracture occurring is 
increased twenty fold. 
While decreased BMD is certainly an important prediction of fracture risk, it is not the only 
parameter to consider. Fracture risk is also associated with a history of falls, low physical function such 
as slow gait speed and decreased quadriceps, impaired cognition and vision, and the presence of 
environmental hazards [3]. 
A. BMD in HIV infected individuals prior to use of Highly Active Anti Retroviral Therapy 
(HAART) 
Prior to the widespread use of HAART, studies indicated that bone metabolism was altered, albeit 
minimally, in HIV infected individuals. Before the availability of protease inhibitors (PIs), low BMD 
was rarely observed in HIV infected individuals. However, the role of HAART in the reduction of 
BMD is controversially reported. According to some reports the direct correlation between the use of 
PI and osteoporosis is not so evident. BMD was significantly lower in HIV-seropositive patients in 
comparison with controls in lumbar spine, proximal femur and total body, without significant 
differences among treatment-naive patients and either of the treatment groups. Only time with HIV 
infection and not specific therapy was associated with BMD decreases [83] patients not receiving 
antiretrovirals also have a higher than expected prevalence of reduced BMD, which suggests that HIV 
itself may be a contributing factor, mediated by immune activation and cytokines [84] 
In one analysis, 45 HIV-infected patients had statistically significant lower lumbar spine BMD 
scores than did HIV-negative controls. The subjects and controls did not differ in total or hip BMD. A 
small decrease in total body BMD was observed in a longitudinal follow up after 15 months. No 
significant reduction was found in spine and hip BMD. This matched the lines of osteopenia rather than 
osteoporosis [85]. But advanced stages of HIV infection demonstrated lower BMD of the individuals 
than HIV-negative controls. Several additional studies suggest a significant prevalence of low BMD in 
HAART-naive patients. This shows the probable role of  HIV infection itself in decreasing BMD. The 
prevalence of osteoporosis in HAART-naive population is found to be approximately 28%, compared 
with the expected 16% in the general population [86-88] 
Studies associated with biochemical markers of bone metabolism and bone biopsy of therapy-
naïve HIV-infected individuals show a significant decrease in osteocalcin, a marker of bone formation 
and a marked increase in C-telopeptide, a marker of bone resorption in a comparison with healthy HIV-
seronegative controls. These facts correlate with enhanced activation of the tumor necrosis factor 
system and increasing severity of HIV disease [89-91]. Numerous cytokines are known to induce 
differentiation of bone marrow precursors into osteoclasts. Hence bone resorption and osteoporosis are 
probably favoured. Abnormal immune system activation may be one of the probable causes that lead to 
bone resorption. 
A study of bone samples from anti-retroviral therapy-naïve HIV infected subjects compared with 
healthy controls showed only decreased levels of osteocalcin in individuals with lower CD4 counts. No 
alterations in BMD or biochemical differences in bone metabolism were demonstrated [92].  Int. J. Med. Sci. 2004 1(3): 152-164  158 
B. BMD in HIV infected individuals after the use of HAART 
A cross-sectional analysis of whole body, lumbar spine and proximal femur BMD in male subjects 
receiving HAART that included a protease inhibitor (PI), HIV-infected patients not receiving a PI and 
healthy seronegative adults using dual x-ray absorptiometry (DXA)  scans was performed. Men 
receiving PI had lower lumbar spine BMD compared with the other two groups. 50% of the subjects on 
PIs were classified as osteopenic or osteoporotic according to WHO classification [13]. An assessment 
of bone metabolism in HIV infected subjects receiving HAART with 2 nucleosides and a PI [93] 
showed 43% of the subjects to be osteopenic or osteoporotic according to the WHO definition. 
Increased markers of bone resorption and bone formation, including elevations in urine pyridinolines, 
bone alkaline phosphatase, and osteocalcin. Another study in HIV-infected children also demonstrated 
HAART-associated losses in BMD that were associated with an increased rate of bone turnover [94]. 
Other studies have shown a more accelerated loss of BMD in individuals receiving potent antiretroviral 
therapy, but the association with PI use remains speculative and needs to be confirmed [14-15]. 
It is impossible to attribute cause and effect and to measure the cumulative effects of other 
important but common risk factors for BMD loss in HIV-infected individuals. Prospective and 
longitudinal studies are necessary to  determine the exact nature and mechanism of each individual 
factor in the pathogenesis of HIV-related bone mineral loss. 
5.   ASSESSMENT OF BONE REMODELING 
Bone remodeling can be assessed using surrogate markers of bone turnover in the blood or urine. 
These markers include bone-specific alkaline phosphatase and osteocalcin, which are indices of bone 
formation. There are also urinary levels of pyridinolines and deoxypyridinolines and serum and urine 
levels of type 1 collagen telopeptides (CTX and NTX), which are indices of bone resorption. The level 
of these markers may identify changes in bone remodeling within a relatively short time - several days 
to months - before changes in bone density can be detected. It is important to realize, however, that 
marker levels cannot predict fracture risk and are only weakly associated with changes in bone mass. 
Therefore, they are of limited utility in the clinical evaluation of individual parametres [3]. 
6.  CLINICAL MANAGEMENT 
Current diagnosis and treatment of osteoporosis is primarily based on recommendations used for 
the management of disease in HIV-seronegative adults. Measurement of BMD as a routine test in HIV-
infected patients is not recommended. However, plain radiographs and magnetic resonance imaging are 
the cornerstones of diagnosis. A detailed history of the past, physical examination, evaluation of 
nutritional status and potential secondary causes of osteoporosis are to be taken into consideration 
before the onset of the treatment of HIV-infected patients. Abnormal laboratory values of elevated 
alkaline phosphatase or low testosterone obtained during the course of HIV treatment should not be 
ignored during treatment [94].   The primary diagnosis of osteoporosis is based on the WHO definitions 
according to measurements of BMD.  The most widely used technique for determining BMD is DXA. 
DXA scanning measures bone mass and density in central regions of interest (hip and spine) as well as 
appendicular regions (wrist, forearm, heel). It has become the gold standard to which all other bone 
densitometry techniques are compared [95-97] Techniques for determining bone mineral density at 
various sites are summarized in Table 2. DXA studies are also useful to define fracture risk as well as 
to measure the efectiveness of various therapies on bone mass. Biochemical markers of bone turnover 
can provide complemetnary information to DXA scans, including changes in bone remodeling that can 
be identified before changes in BMD [1]. However the exact effectiveness of such markers remains 
controversial. 
Table 2: Techniques for determining bone mineral density at various sites 
Technique Sites 
Central dual-energy x-ray absorptiometry  Spine, hip, whole body 
Peripheral dual-energy x-ray absorptiometry  Middle finger, wrist, heel, forearm 
Single-energy x-ray absorptiometry  Forearm, heel 
Quantitative computed tomography  Trabecular bone only; vertebral body Int. J. Med. Sci. 2004 1(3): 152-164  159 
Peripheral quantitative computed tomography  Forearm 
Ultrasound  Heel, patella, ankle 
  
Management is dependent on the stage of bone disease and ranges from observation to total joint 
arthroplasty. Clinicians may help to prevent HIV-associated osteonecrosis by encouraging patients to 
limit their exposure to the established risk factors for the disease [98]. The treatment strategies that are 
effective in the general population should be pursued. Reversible causes of secondary osteoporosis 
should be studied. Vitamin D and calcium intake should be optimized. Other nutrients are also 
important in relation to bone health. Diets with very high protein content, excess caffeine, phosphorus, 
and sodium can increase calcium losses. Moderate physical activity is also recommended. The 
treatment for such conditions usually follows the general lines of management of osteoporosis [1].  
Patients undergoing long-term corticosteroid treatment should begin primary prevention measures 
as soon as such agents are prescribed. Attempts to preserve bone should not be delayed until the 
underlying disease process is under way. Any patient taking glucocorticoids who has a T score of less 
than -1.0 should immediately be given pharmacologic treatment [99]. The most commonly used 
pharmacologic treatments for osteoporosis (excluding calcium and vitamin D supplements) are 
antiresorptive agents (estrogen, bisphosphonates, calcitonins, and selective estrogen receptor 
modulators). Other agents under development or already in use outside the United States include 
fluoride salts, parathyroid hormone, active forms of vitamin D (calcitriol, alfacalcidol), and anabolic 
steroids.  
HRT  
The utility of HRT (estrogen) for prevention of bone loss in early menopause is well established. HRT 
that is started at menopause retards or prevents bone loss and increases BMD somewhat. HRT 
continues to prevent bone loss for as long as it is taken, but bone loss resumes when estrogen is 
discontinued [100,101]. HRT is also effective in older women with established osteoporosis. Added 
potential benefits of HRT include controlling menopausal symptoms and reducing the risk of heart 
disease. Despite its documented benefits, however, some women find that the side-effect profile of 
HRT (eg, breast tenderness, abnormal uterine bleeding, endometrial hyperplasia, migraine, deep venous 
thrombosis) is unacceptable. Additionally, women may fear the relationship between HRT and breast 
cancer. Nevertheless, hormone replacement is considered first-line therapy in most postmenopausal 
patients.  
Bisphosphonates  
Candidates for bisphosphonate treatment include premenopausal women at increased risk for 
osteoporosis, postmenopausal women who forgo HRT, men with osteoporosis [102,103], and all 
individuals receiving high-dose corticosteroid therapy. In controlled clinical trials [104,105], 
bisphosphonates reduced the risk of fractures of the spine, hip, and wrist by 40% to 50% in 
postmenopausal women. These data are particularly significant because no randomized clinical trials 
have actually measured the effect of HRT on hip fracture, the most serious consequence of 
osteoporosis, even though observed studies consistently show that postmenopausal women who have 
been receiving HRT for 5 to 10 years have a lower risk of hip fracture than their counterparts who have 
not [106]  
Several studies have shown bisphosphonates to be highly effective for prevention of 
glucocorticoid-induced bone loss, and these drugs have been approved by the US Food and Drug  
Administration (FDA) for this indication.   Risedronate sodium (Actonel), a pyridinyl 
bisphosphonate with FDA approval for the treatment of Paget's disease of bone, has recently been 
approved for prevention and treatment of postmenopausal and glucocorticoid-induced osteoporosis. 
Recent data from two controlled studies showed that this agent reduced the incidence of vertebral 
fractures by 70% in patients beginning corticosteroid therapy (when bone loss is most rapid) compared 
with controls [107]. 
Clinical experience with bisphosphonates has shown that patients may experience upper 
gastrointestinal disturbance, particularly esophageal symptoms (heartburn, painful or difficult 
swallowing) .Alendronate sodium (Fosamax) should be taken with 6 to 8 oz of plain water at least one-Int. J. Med. Sci. 2004 1(3): 152-164  160 
half hour before the first food, beverage, or medication of the day. Other beverages (including mineral 
water), food, and other medications can reduce the absorption of oral bisphosphonates. Also, patients 
should not lie down until at least 30 minutes after taking alendronate and until after the first food of the 
day [108]. Clinical trials of risedronate have included postmenopausal women with ongoing 
gastrointestinal disease and those using aspirin or nonsteroidal anti-inflammatory drugs. Preliminary 
results [109] indicate that the incidence and severity of gastrointestinal events with use of risedronate 
are similar to those reported in the control group. Alternative dosage formulation and administration of 
bisphosphonates is under investigation.  
Calcitonins 
For patients who are unable or choose not to undergo HRT or take a bisphosphonate, a calcitonin is a 
viable alternative. Calcitonin-salmon is administered as a nasal spray (Miacalcin) or by injection. 
Calcitonin prevents bone loss and fracture in established osteoporosis, although it is somewhat less 
effective than HRT and bisphosphonates [110]. Recent results of a large controlled study (Prevent 
Recurrence of Osteoporotic Fracture) showed that calcitonin-salmon nasal spray reduced the incidence 
of new spinal fractures by 36% over a 5-year period, compared with placebo, in postmenopausal 
women who had previously experienced fracture. To date, calcitonin has shown no effect on 
nonvertebral fractures, and it has not been shown to reduce fracture risk in corticosteroid-treated 
patients [111]. However, calcitonin has modest analgesic properties, which may decrease opioid use 
and allow earlier ambulation in patients with acute vertebral fractures.  
Selective estrogen receptor modulators 
A selective estrogen receptor modulator may serve as an alternative to HRT for selected patients. 
Raloxifene (Evista) is the most studied of these drugs to date; its estrogenlike effects increase BMD . 
Raloxifene decreases total and low-density lipoprotein cholesterol levels, but unlike HRT, it does not 
affect high-density lipoprotein cholesterol. Also, unlike HRT, raloxifene does not appear to stimulate 
the endometrium . Recent data from the multiple outcomes of Raloxifene evaluation  showed that 60- 
and 120-mg daily doses of raloxifene significantly decreased vertebral fracture risk during the first 36 
months of treatment, compared with placebo. All patients also received calcium and cholecalciferol. At 
36 months, raloxifene did not significantly lower the risk of nonvertebral fractures compared with 
placebo, although the cumulative incidence of nonvertebral fractures in active and placebo groups 
begins to diverge at 2 years. The effect of raloxifene on hip fracture is under investigation [112,113]. 
Specific studies with HIV-infected individuals should be conducted to determine the most effective 
way of this treatment. 
7.  CONCLUSION 
Osteoporosis has been the recently recognized complication affecting HIV-positive patients. 
Etiology and pathogenesis of osteoporosis in HIV infection are still uncertain. Progression in HIV 
infection and HAART with PI are the possible factors that precipitate osteoporosis in HIV–sero-
positive patients. Further studies should be extended to look into the natural history of bone loss  
during HIV disease. This would help to understand the mechanisms of uncoupled bone turnover and 
effects of PI therapy on HIV infected patients. As the number and life expectancy of HIV-positive 
patients treated with HAART increases, the development and treatment of osteoporosis in HIV 
infection should be taken into consideration in the long term management of HIV disease.  
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